Lexeo Therapeutics (LXEO) Preferred Stock Liabilities (2022 - 2023)

Lexeo Therapeutics has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $99.8 million for Q3 2023.

• Preferred Stock Liabilities for Q3 2023 came in at $99.8 million, down 46.08% year-over-year; the trailing twelve-month figure through Sep 2023 was $99.8 million (down 46.08% YoY), and the FY2022 annual result was $185.0 million, changed N/A from the prior year.
• Preferred Stock Liabilities came in at $99.8 million for Q3 2023 at Lexeo Therapeutics, down from $185.0 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $185.0 million in Q3 2022 to a low of $99.8 million in Q3 2023.